Stability of patients' preferences for chemotherapy: The impact of experience

被引:62
作者
Jansen, SJT
Kievit, J
Nooij, MA
Stiggelbout, AM
机构
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Med Decis Making, NL-2300 RC Leiden, Netherlands
关键词
stability; utility assessment; standard gamble; time trade-off;
D O I
10.1177/02729890122062596
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background. Studies have shown that utilities for a particular treatment, elicited by means of a hypothetical treatment scenario, may remain stable within the same patients when examined before, during, and after experiencing that treatment (within-group stability). However, other studies have found that utilities for a particular health state may differ between patient groups who are and who are not experiencing the particular health state (between group differences). Objective. The authors evaluated this apparent contradiction in the case of adjuvant chemotherapy for breast cancer. A related purpose was to examine whether a chemotherapy scenario adequately reflects the patients' own experiences with chemotherapy. Method. Forty-three patients with early-stage breast cancer evaluated their actually experienced health state and a chemotherapy scenario before, during, and after undergoing adjuvant chemotherapy (chemotherapy group). A control group of 51 patients for whom chemotherapy was not part of the treatment plan was interviewed at similar points in time. Utlities were elicited by means of a visual analog scale (VAS), a chained time trade-off (TTO), and a chained standard gamble (SG). Results. The utilities for the chemotherapy scenario remained relatively stable over time in the 2 patient groups. Furthermore, the chemotherapy scenario was evaluated more positively by patients in the chemotherapy group than by control patients (e.g., utilities before chemotherapy: VAS 0.69 vs. 0.50, TTO 0.88 vs. 0.50, SG 0.92 vs. 0.58, all Ps < 0.01). Finally, patients in the chemotherapy group evaluated their actually experienced health states during chemotherapy higher than the chemotherapy scenario that was assessed at the same time (VAS 0.79 vs. 0.69, TTO 0.93 vs. 0.87, SG 0.97 vs. 0.96, all Ps < 0.05). Conclusions. Both within-group stability and between-group differences were found. A possible explanation for within-group stability may be that the chemotherapy scenario did not fully correspond to the patients' actual experiences with chemotherapy ("noncorresponding description"). Therefore, preferences did not change even when the patients' own clinical health status had changed. The between-group differences may be explained by "anticipated adaptation." Both explanations may work together to explain why utilities remain stable within the same patients but differ between different patient groups.
引用
收藏
页码:295 / 306
页数:12
相关论文
共 48 条
  • [1] Abe O, 1998, LANCET, V352, P930
  • [2] THE TIME TRADE-OFF TECHNIQUE - HOW DO THE VALUATIONS OF BREAST-CANCER PATIENTS COMPARE TO THOSE OF OTHER GROUPS
    ASHBY, J
    OHANLON, M
    BUXTON, MJ
    [J]. QUALITY OF LIFE RESEARCH, 1994, 3 (04) : 257 - 265
  • [3] Feasibility, validity and test-retest reliability of scaling methods for health states: The visual analogue scale and the time trade-off
    Badia, X
    Monserrat, S
    Roset, M
    Herdman, M
    [J]. QUALITY OF LIFE RESEARCH, 1999, 8 (04) : 303 - 310
  • [4] Berkowitz L., 1986, A Survey of Social Psychology
  • [5] AURANOFIN THERAPY AND QUALITY-OF-LIFE IN PATIENTS WITH RHEUMATOID-ARTHRITIS - RESULTS OF A MULTICENTER TRIAL
    BOMBARDIER, C
    WARE, J
    RUSSELL, IJ
    LARSON, M
    CHALMERS, A
    READ, JL
    [J]. AMERICAN JOURNAL OF MEDICINE, 1986, 81 (04) : 565 - 578
  • [6] WHOSE UTILITIES FOR DECISION-ANALYSIS
    BOYD, NF
    SUTHERLAND, HJ
    HEASMAN, KZ
    TRITCHLER, DL
    CUMMINGS, BJ
    [J]. MEDICAL DECISION MAKING, 1990, 10 (01) : 58 - 67
  • [7] Prostate cancer patients' utilities for health states: How it looks depends on where you stand
    Chapman, GB
    Elstein, AS
    Kuzel, TM
    Sharifi, R
    Nadler, RB
    Andrews, A
    Bennett, CL
    [J]. MEDICAL DECISION MAKING, 1998, 18 (03) : 278 - 286
  • [8] De Wit GA, 2000, HEALTH ECON, V9, P109, DOI 10.1002/(SICI)1099-1050(200003)9:2<109::AID-HEC503>3.0.CO
  • [9] 2-L
  • [10] Adjuvant cytotoxic chemotherapy for early breast cancer: doubts and decisions
    Dodwell, DJ
    [J]. LANCET, 1998, 351 (9114) : 1506 - 1507